The Force Frequency Relationship in Heart Failure and Diabetes Mellitus: a Metabolic Aetiology?
NCT07309523
Summary
The present investigation is a non-randomised, observational study involving an unselected but highly phenotyped cohort of patients undergoing pacemaker or defibrillator implantation from whom a small sample of fat and muscle will be taken from the operation site, and, in a subgroup, from the thigh muscle. A sample of blood wil also be taken from the vein of the heart, a peripheral vein and the artery at the wrist during the procedure at different heart rates and pacing modes, to describe how heart rate and heart contraction power relate to cardiac and peripheral metabolism. The coded blood and tissue samples and anonymised clinical data will be stored in a Human Tissue Authority-approved freezer until analysis. Following the procedure, during routine visits, patients' left ventricular force frequency relationship will be assessed using cardiac ultrasound and a non-invasive cardiac monitor to further phenotype the severity and progression of their heart function over 6 months. For most patients, their involvement will end at that point although they will be monitored through electronic health records on an annual basis from that point forward for up to 5 years after the end of the study (for up to ten years after that point) to gain information on the prognostic value of the metabolic and haemodynamic testing. The present investigation will allow the investigators to advance the understanding of heart-muscle crosstalk with the goal of developing targeted interventions that could open new treatment avenues.
Eligibility
Inclusion Criteria: * Guideline-compliant, clinical indication for pacemaker implantation * Age \>18 years * Ability to provide written informed consent * Persons who are legally competent and mentally able to follow the instructions of the study staff Exclusion Criteria: * Anemia Hb \<8 mg/dl * Patients with acute infectious diseases (e.g. pneumonia) * Patients with heart failure due to sepsis * People with acute myocardial ischemia, which is manifested, for example, by angina pectoris or ECG changes under stress * Patients with acute liver or kidney failure * Pregnant and breastfeeding women * People who are institutionalized on official or court orders * People who are dependent or employed by the sponsor or investigator * Taking study medication (of an investigational drug) 30 days before the start of the study * Known contrast allergy or eGFR \<20ml/min/1.73m2 * Pregnancy not excluded by bedside pregnancy test in premenopausal women
Conditions4
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07309523